Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy of acute treatment with 10 mg/day vortioxetine versus placebo on
cognitive performance (focusing on the aspect concerning speed of processing, executive
functioning, attention) in working patients with major depressive disorder (MDD).